MedTrace Logo

Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.

NCT06716775 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-12-04

No results posted yet for this study

Summary

This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the treatment of brain metastases from non-small cell lung cancer (NSCLC) .

Conditions

  • NSCLC Brain Metastasis

Interventions

DEVICE

Tumor treating felds (TTF)

Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.

OTHER

Best Standard of Care

Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Jiangsu Healthy Life Innovation Medical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2028-06-30
Completion
2028-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716775 on ClinicalTrials.gov